IMMUNE CHECKPOINT INHIBITORS
Clinical trials for IMMUNE CHECKPOINT INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITORS trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radiation approach aims to boost lung cancer treatment in poor responders
Disease control Not yet recruitingThis phase II trial tests a special type of radiation called lattice radiation therapy (LRT) combined with standard chemoimmunotherapy for people with stage III lung cancer that did not shrink enough after initial treatment. The LRT delivers high-dose radiation to specific spots …
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can a cancer drug wake up immune cells to beat HIV-Related infections?
Disease control Not yet recruitingThis study tests a drug called Sintilimab, which is normally used for cancer, to see if it can help people with HIV who have infections that won't go away with standard treatment. The drug works by 'waking up' exhausted immune cells. Fifty adults with HIV and a hard-to-treat infe…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New breast cancer trial aims to spare heart toxicity with smart drug strategy
Disease control Not yet recruitingThis Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possib…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cocktail of drugs targets Hard-to-Treat bile duct cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—disitamab vedotin, lenvatinib, and a PD-1 inhibitor—for people with HER2-positive advanced biliary tract cancer that cannot be removed by surgery. The study will enroll 65 participants to see how well the treatment shrinks tum…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:45 UTC